全文获取类型
收费全文 | 310篇 |
免费 | 19篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 13篇 |
妇产科学 | 6篇 |
基础医学 | 20篇 |
口腔科学 | 3篇 |
临床医学 | 42篇 |
内科学 | 57篇 |
皮肤病学 | 3篇 |
神经病学 | 23篇 |
特种医学 | 26篇 |
外科学 | 40篇 |
综合类 | 18篇 |
预防医学 | 16篇 |
眼科学 | 3篇 |
药学 | 31篇 |
肿瘤学 | 29篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 9篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 8篇 |
2017年 | 6篇 |
2016年 | 11篇 |
2015年 | 10篇 |
2014年 | 10篇 |
2013年 | 15篇 |
2012年 | 17篇 |
2011年 | 21篇 |
2010年 | 8篇 |
2009年 | 21篇 |
2008年 | 21篇 |
2007年 | 9篇 |
2006年 | 10篇 |
2005年 | 13篇 |
2004年 | 4篇 |
2003年 | 7篇 |
2002年 | 4篇 |
2001年 | 12篇 |
2000年 | 7篇 |
1999年 | 6篇 |
1998年 | 18篇 |
1997年 | 15篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 10篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 5篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有332条查询结果,搜索用时 15 毫秒
91.
Lassiter LK Tummala MK Hussain MH Stadler WM Petrylak DP Carducci MA 《Clinical genitourinary cancer》2008,6(1):31-35
BACKGROUND: Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. PATIENTS AND METHODS: Eligible patients included those with bi-dimensionally measurable disease and an Eastern Cooperative Oncology Group performance status of 0-2, transitional cell carcinoma or adenocarcinoma of the urothelium, and nonresponse to > or = 1 previous standard chemotherapy regimen. Patients received piritrexim orally at 25 mg 3 times daily (every 8 hours regularly) for 5 consecutive days each week for 3 weeks, followed by a 1-week rest period. Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. RESULTS: Of the 23 patients enrolled, 19 patients and 22 patients were assessable for toxicity and response, respectively. Two patients required dose reduction because of toxicity, 2 patients discontinued study because of toxicity, and 6 patients had > or = 1 serious adverse event. Except for grade 1/2 pain and fatigue, gastrointestinal toxicities were the most commonly reported events, followed by fever, delirium, and myelosuppression. No objective responses were observed, with 2 patients demonstrating stable disease after 2-4 cycles. By the statistical design of the trial, further enrollment was halted because of lack of activity. CONCLUSION: Regardless of modest side effects, oral piritrexim in heavily pretreated patients is inactive at this dose and schedule, confirming the results of a recent cooperative group trial. 相似文献
92.
93.
94.
95.
Lymphokine abnormalities in aplastic anemia: implications for the mechanism of action of antithymocyte globulin 总被引:1,自引:1,他引:1
Anti-thymocyte globulin (ATG) provides effective therapy for many patients with aplastic anemia, and its mechanism of action has been presumed to be secondary to lymphocytotoxicity. However, our studies of lymphocyte function in aplastic anemia show marked abnormalities of lymphokine production, which ATG may modulate. In 12 of 17 patients with aplastic anemia, interleukin 2 (IL2) production was markedly elevated in vitro (P less than .01 by paired statistical analysis). Expression of the IL2 receptor, or Tac antigen, on peripheral lymphocytes assessed by flow microfluorometry was also increased above the normal range in 11 of 15 cases. Studies of ATG suggested that it might act to stimulate lymphocyte function. In vitro, ATG is a mitogen, as measured by incorporation of 3H-thymidine into blood mononuclear cells; the response of cells to ATG from patients with aplastic anemia was exaggerated in comparison with normals. Cell proliferation was accompanied by production of IL2 to levels that were, in some cases, similar to those obtained with lectin stimulation. Finally, supernatants from lymphocytes cultured in the presence of ATG were able to replace adherent cells in providing growth factors for the support of nonadherent cells in methylcellulose hematopoietic colony assays. These results provide a mechanism for an "immunostimulatory" action of ATG in effecting hematopoietic response in some patients with aplastic anemia. 相似文献
96.
Krishna NB Tummala P Mehan CD Reddy AV Hartman JA Agarwal B 《Journal of gastrointestinal surgery》2012,16(4):793-800
Background
Management of small and potentially resectable “mass” lesions encountered on CT/MRI scans in patients without obstructive jaundice (ObJ) is rather empirical since there is scant data on likelihood of neoplasm to formulate treatment strategies. We evaluated (1) the prevalence of neoplasm and (2) performance characteristics of EUS-FNA for diagnosing neoplasm in above-mentioned subset of patients. 相似文献97.
98.
99.
100.
Ramyashree Tummala Manasvi Gupta Arvind Reddy Devanabanda Dhrubajyoti Bandyopadhyay Wilbert S. Aronow Kausik K. Ray Mamas Mamas Raktim K. Ghosh 《Annals of medicine》2022,54(1):1287
Atherosclerotic heart disease is the leading cause of mortality and morbidity in the USA. Low density lipoprotein (LDL) has been the target for many hypolipidemic agents to modify atherosclerotic risk. Bempedoic acid is a novel hypolipidemic drug that inhibits the enzymatic activity of ATP citrate lyase in the cholesterol synthesis pathway. CLEAR Harmony, CLEAR Wisdom, CLEAR Tranquillity and CLEAR Serenity have shown safety and efficacy associated with long term administration of this drug. Studies have shown effectiveness in reducing LDL-C in both statin intolerant patients and in patients on maximally tolerated doses of statin. The fixed drug combination of bempedoic acid and ezetimibe in a recent phase III showed significant reduction in LDL compared with placebo, which might be a promising future for LDL reduction among statin intolerant patients. Bempedoic acid also reduced inflammatory markers like hs-CRP. Given these results, bempedoic acid alone and in combination with ezetimibe received the USA FDA approval for adults with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease. We present a comprehensive review exploring the underlying mechanism, pre-clinical studies, and clinical trials of bempedoic acid and discuss the potential future role of the drug in treating hyperlipidaemia. 相似文献